Ukoniq™ (umbralisib) – New orphan drug approval
February 5, 2021 - TG Therapeutics announced the FDA approval of Ukoniq (umbralisib), for the treatment of adult patients with: (1) relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen or (2) relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Top